← Eichor
Study identifier: NCT06809283 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Observational Prospective PMCF Study to Confirm Performance and Safety of Intelect® Devices in Real World

Condition: Musculoskeletal Disorders · Skeletal Disorder · Muscle Disorder  ·  Sponsor: DJO UK Ltd

PhaseN/A
Planned participants144
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

DJO UK Ltd (ENOVIS) is conducting this study to confirm the performance and safety of the Chattanooga Intelect® devices in real world use. This study will record post market clinical data on the use of a number of MDR-CE marked devices that are part of the Chattanooga Intelect® device family to ensure the continued acceptability of the benefit-risk ratio, and to identify possible systematic misuse or off-label use of the devices (Intelect® Mobile 2 Combo, Intelect® Mobile 2 Ultrasound, Intelect® Mobile 2 Electrotherapy (Stim), Intelect® Transport 2 Combo and Intelect® Transport 2 Ultrasound).

This description comes directly from the study's public registry record.

Talk to the study team

Elena Arcangeli  ·  3498772528  ·  elena.arcangeli@enovis.com

Always discuss trial participation with your own doctor first.

Locations (4)

Attal CabinetSerris, FranceCompleted
CasertafisioCaserta, ItalyRecruiting
Rachis CenterRoma, ItalyRecruiting
Dr Chad Woods PhysiotherapyPeebles, United KingdomRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06809283